期刊文献+

急性移植物抗宿主病患者发生移植相关血栓性微血管病的危险因素及预后分析 被引量:8

The risk factors and prognosis of transplant-associated thrombotic microangiopathy following acute graft-versus-host disease
原文传递
导出
摘要 目的 探讨急性移植物抗宿主病(aGVHD)患者中移植相关血栓性微血管病(TA-TMA)发生的危险因素和影响TA-TMA预后的因素。方法 选取356例在北京大学血液病研究所接受异基因造血干细胞移植后发生aGVHD的患者为研究人群,选取33例移植后发生TA-TMA的患者作为病例组,以危险集抽样的方法在同一队列中随机选取年龄和随访时间匹配的患者组成对照组(77例)。比较两组间的危险因素和预后情况。结果 TA-TMA的中位发生时间为移植后3.5(1.2-23.0)个月。TA-TMA发病距aGVHD诊断的中位时间为25(7-257)d。aGVHD发生时间、起始严重程度、一线治疗失败及二线治疗中使用他克莫司与aGVHD患者发生TA-TMA独立相关,具有2种以上危险因素的患者TA-TMA风险明显升高(OR=210.0,P=0.000)。22例(66.7%)TA-TMA患者死亡,而进展型TA-TMA是预后的惟一不良影响因素。各种治疗方法均不能改善TA-TMA患者的预后。结论 aGVHD的多种特点与TA-TMA相关,便于筛选出aGVHD合并TA-TMA的高危患者,并指导选择更合理的治疗方案。 Objective To investigate the risk factors and prognosis of transplant-associated thrombotic microangiopathy (TA-TMA) following acute graft-versus-host disease (aGVHD), and to evaluate the factors that might influence the prognosis of TA-TMA.Methods A nested case-control study was designed. Cases with TA-TMA (n=33) and controls (n=77) matched for age at allogeneic hematopoietic stem cell transplantation (allo-HSCT) and length of follow-up were identified from a cohort of 356 patients who suffered from aGVHD after allo-HSCT between 2009 and 2011.Results The median time to presentation of TA-TMA was 3.5 (1.2-23.0) months post-HSCT. The median time from diagnosis and first-line treatment failure of aGVHD to TA-TMA diagnosis was 25 (7-257) days and 15(5-257) days, respectively. aGVHD occurring beyond 60 days after allo-HSCT, initial grade Ⅲ-Ⅳ aGVHD, first-line treatment failure and receiving tacrolimus as second-line treatment were independently associated with the occurrence of TA-TMA, and patients with two or more risk factors were at higher risk (OR=210.0, P=0.000). Twenty-two(66.7%) TA-TMA patients died. Progressive TA-TMA was the significantly adverse factor affecting the survival of TA-TMA cases. None of therapies could improve prognosis of patients with TA-TMA.Conclusion Many characteristics of aGVHD were associated with TA-TMA, which help us to identify the individuals who are at higher risk of developing TA-TMA following aGVHD and to select the more reasonable GVHD therapeutic strategies.
出处 《中华内科杂志》 CAS CSCD 北大核心 2013年第2期156-160,共5页 Chinese Journal of Internal Medicine
基金 国家自然科学基金(30971292) 国家863计划项目(2011AA020105)
关键词 移植物抗宿主病 血栓性微血管病 造血干细胞移植 异基因 Graft vs host disease Thrombotic microangiopathy Hematopoietic stem celltransplantation, a11ogeneie
  • 相关文献

参考文献31

  • 1Batts ED, Lazarus HM. Diagnosis and treatment of transplantation- associated thrombotic microangiopathy: real progress or are we still waiting.'?. Bone Marrow Transplant, 2007,40:709-719.
  • 2Stavrou E, Lazarus HM. Thrombotic microangiopathy in haematopoietie cell transplantation : an update. Mediterr J Hematol Infect Dis, 2010,2 : e2010033.
  • 3Daly AS, Xenoeostas A, Lipton JH. Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant, 2002,30:709-715.
  • 4Paquette RL, Tran L, Landaw EM. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Bone Marrow Transplant, 1998,22:351-357.
  • 5Daly AS, Hasegawa WS, Lipton JH, et al. Transplantation- associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver. Transfus Apher Sci, 2002,27:3-12.
  • 6Willems E, Baron F, Seidel L, et al. Comparison of thrombotic mieroangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Bone Marrow Transplant. 2010.45:689 -693.
  • 7Martinez MT, Bucher Ch, Stussi G, et al. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant, 2005,36 : 993- 1000.
  • 8Uderzo C, Bonanomi S, Busca A, et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation, 2006, 82:638-644.
  • 9Nishida T, Hamaguchi M, Hirabayashi N, et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation : a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant, 2004, 33 : 1143-1150.
  • 10Nakamae H, Yamane T, Hasegawa T, et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol, 2006,81:525-531.

同被引文献72

  • 1吴涛,白海,王存邦,路继红,欧剑锋.骨髓间充质干细胞培养上清对异体淋巴细胞增殖的影响[J].中华微生物学和免疫学杂志,2005,25(7):563-563. 被引量:5
  • 2吴涛,白海,王存邦,路继红,欧剑锋.成人骨髓间充质干细胞抑制异体淋巴细胞增殖的实验研究[J].中华器官移植杂志,2006,27(2):111-113. 被引量:16
  • 3董陆佳,谢大鹤,陆道培,陈欢,高志勇,陈育红,吴彤,韩伟,张晓辉,赵艳丽.造血干细胞移植相关性肠道血栓性微血管病:临床病理学特征、诊断标准和治疗[J].中国实验血液学杂志,2006,14(2):327-331. 被引量:8
  • 4Deeg H J,Seidel K,Bruemmer B,et al.Impact of patient weight on non-relapse mortality after marrow transplantation[J].Bone Marrow Transplant,1995,15:461-468.
  • 5Navarro WH,Agovi MA,Logan BR,et al.Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults[J].Biol Blood Marrow Transplant,2010,16:1442-1450.
  • 6Fuji S,Kim SW,Yoshimura K,et al.Possible association between obesity and posttransplantation complications including infectious diseases and acute graft-versus-host disease[J].Biol Blood Marrow Transplant,2009,15:73-82.
  • 7Sorror ML,Giralt S,Sandmaier BM,et al.Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission:combined FHCRC and MDACC experiences[J].Blood,2007,110:4606-4613.
  • 8Huang X J,Liu DH,Liu KY,et al.Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies[J].Bone Marrow Transplant,2006,38:291-297.
  • 9Spitzer TR.Engraftment syndrome following hematopoietie stem cell transplantation[J].Bone Marrow Transplant,2001,27:893-898.
  • 10Wang Y,Liu DH,Liu KY,et al.Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia:nine years of experience at a single center[J].Cancer,2013,119:978-985.

引证文献8

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部